^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TST010
i
Other names: TST010
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Transcenta
Drug class:
Immunomodulator
Related drugs:
almost2years
ADCC enhanced anti-CD25 mAb (TST010) demonstrated antitumor activity via depleting Treg cells and increasing CD8+T/Treg ratio in preclinical tumor models (AACR 2023)
In summary, we have discovered a novel therapeutic anti-CD25 mAb that can deplete Treg cells without blocking IL-2 signaling. As demonstrated in our preclinical tumor models, it has a good potential to induce effective antitumor immune responses in TME and tumor growth inhibition especially in combination with PD-1/PD-L1 treatment.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • FOXP3 (Forkhead Box P3)
|
IL2RA expression • CD2 overexpression • IL2R overexpression • FOXP3 expression
|
TST010
Share via
